Omalizumab as a treatment option for antihistamine-refractory aquagenic urticaria.

Abstract

A teenage girl presented with symptoms of itching and hives on contact with water for 3 years. On specific provocative testing and ruling out underlying systemic conditions, she was diagnosed with aquagenic urticaria. Following failed attempts to control her symptoms with second-generation antihistamines, she was started on monthly subcutaneous injections of the monoclonal antibody, omalizumab. The patient demonstrated significant improvement, with symptoms being well-controlled for 2 years now. She enjoys a good quality of life and can take a shower without developing itching or hives.

• Authors: Sehajpreet Kaur, Iktej Singh Jabbal, Arveen Kaur Bhasin
• Journal: BMJ case reports (BMJ Case Rep) Vol. 15 Issue 7 (Jul 18 2022) ISSN: 1757-790X [Electronic] England
• PMID: 35850790 (Publication Type: Case Reports, Journal Article)
• Copyright: © BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Chemical References

• Anti-Allergic Agents
• Histamine Antagonists
• Histamine H1 Antagonists
• Omalizumab

Topics

• Adolescent
• Anti-Allergic Agents (therapeutic use)
• Chronic Disease
• Female
• Histamine Antagonists (therapeutic use)
• Histamine H1 Antagonists (therapeutic use)
• Humans
• Omalizumab (therapeutic use)
• Pruritus
• Quality of Life
• Treatment Outcome
• Urticaria (drug therapy, etiology)
• Chronic Inducible Urticaria